Helicobacter pylori and Clinical Aspects of Gastric Cancer
- 25 August 2009
- journal article
- review article
- Published by Wiley in Helicobacter
- Vol. 14 (s1) , 41-45
Abstract
In spite of important new insights into the basic mechanisms of gastric carcinogenesis, progress in the management of gastric cancer has been modest. Some modifications in the chemotherapies used for palliation and strategies for downstaging of the disease prior to surgical intervention are noteworthy. The positive experience with endoscopic mucosal resection (EMR) and submucosal dissection (ESD) for treatment of early gastric cancer has been confirmed and extended. The procedure‐related morbidity and post‐interventional quality of life is clearly favorable compared to open surgical resection in well‐selected patients. New data on Helicobacter pylori revealed that eradication after endoscopic resection of early gastric cancer significantly reduces the incidence of recurrent and metachronous gastric neoplasias. It can further improve healing rates of treatment induced gastric ulcers. Eradication therapy therefore remains the best target for prevention of the disease. Critical is the “point of no return” when mucosal alterations (i.e. intestinal metaplasia, glandular atrophy) are no longer reversible. A population‐based screen‐and‐eradicate strategy for H. pylori infection can at present only be recommended in high incidence regions.Keywords
This publication has 31 references indexed in Scilit:
- Helicobacter pylori Eradication Therapy May Facilitate Gastric Ulcer Healing After Endoscopic Mucosal Resection: A Prospective Randomized StudyHelicobacter, 2008
- The Impact of Comorbidity on Surgical Outcomes in Laparoscopy-Assisted Distal GastrectomyAnnals of Surgery, 2008
- Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancerSurgery Today, 2008
- Treatment strategy after non-curative endoscopic resection of early gastric cancerBritish Journal of Surgery, 2008
- Curability of laparoscopic gastrectomy for gastric cancer: an analysis of 10 years’ experienceGastric Cancer, 2008
- Exploring the cost‐effectiveness ofHelicobacter pyloriscreening to prevent gastric cancer in China in anticipation of clinical trial resultsInternational Journal of Cancer, 2008
- Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancerBritish Journal of Cancer, 2008
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Systematic review: Helicobacter pylori eradication for the prevention of gastric cancerAlimentary Pharmacology & Therapeutics, 2006
- Long term follow up of patients treated for Helicobacter pylori infectionGut, 2005